Suppr超能文献

催乳素分泌型垂体腺瘤手术治疗的预后因素

Prognostic factors for surgical treatment of prolactin-secreting pituitary adenomas.

作者信息

Voznyak Oleksandr, Zinkevych Iaroslav, Lytvynenko Andrii, Hryniv Nazarii, Ilyuk Roman, Kobyliak Nazarii

机构信息

Centre of Neurosurgery, Clinical Hospital "Feofaniya", Kyiv, Ukraine.

Medical Laboratory CSD, Kyiv, Ukraine.

出版信息

Front Surg. 2024 Feb 5;11:1283179. doi: 10.3389/fsurg.2024.1283179. eCollection 2024.

Abstract

INTRODUCTION

Usually, prolactinomas are treated with dopamine agonists (DA). Surgery is considered an option when the patient cannot bear or does not respond positively to DA therapy.

AIM

This study aims to determine the early and late outcomes of surgery, with particular emphasis on developing prognostic factors for surgical treatment and analyzing risk factors affecting the recurrence of hyperprolactinemia and prolactinoma.

MATERIAL AND METHODS

This retrospective study was conducted at the Feofaniya Clinical Hospital of the State Administration of Affairs (Kyiv, Ukraine), evaluating 109 patients' records from 2009 to 2019. The main patients' inclusion criteria were: serum prolactin (PRL) level of more than 100 ng/ml, presence of pituitary adenoma (PA) on MRI, histologically approved PA by microscopy. According to the size of the prolactin-secreting PA (PSPAs) the selected 109 patients were divided into two groups: micro- (≤10 mm,  = 75) and macroadenoma group (10-40 mm,  = 34).

RESULTS

1 month after the operation, PRL levels decreased by 87% ( < 0.001), 12 months-by 93% ( < 0.001). After receiving surgery and DA therapy for 12 months 77.1% of patients achieved biochemical remission. Out of the total number of patients observed, 15.6% ( = 17) had a Knosp score greater than 3. Additionally, in the macroadenoma group, the percentage of patients with a Knosp score greater than 3 was 41,2%, which was significantly higher as compared to the microadenoma group (4%,  < 0.001). In patients with microadenomas a weak reverse correlation between patients' age ( = -0.258,  < 0.026) and positive with tumor size ( = 0.251,  < 0.030) was revealed. In the macroadenoma group significant association was found only between preoperative serum PRL level and tumor size ( = 0.412,  < 0.016). The preoperative PRL can be used as a diagnostic marker for lack of early biochemical remission in patients with PSPAs with diagnostic accuracy 66.9%.

CONCLUSIONS

This study found that primary transsphenoidal surgery is an effective treatment in reaching PRL level control in patients with both micro- and macroprolactinomas. The correct and thorough selection of candidates for surgery is crucial to achieve postoperative serum PRL normalization in the vast majority of patients.

摘要

引言

通常,泌乳素瘤采用多巴胺激动剂(DA)治疗。当患者无法耐受DA治疗或对其无积极反应时,手术被视为一种选择。

目的

本研究旨在确定手术的早期和晚期结果,特别强调制定手术治疗的预后因素,并分析影响高泌乳素血症和泌乳素瘤复发的危险因素。

材料与方法

本回顾性研究在乌克兰基辅国家事务管理局的费奥法尼亚临床医院进行,评估了2009年至2019年109例患者的病历。患者的主要纳入标准为:血清泌乳素(PRL)水平超过100 ng/ml,MRI显示存在垂体腺瘤(PA),经显微镜组织学证实为PA。根据分泌泌乳素的PA(PSPA)大小,将所选的109例患者分为两组:微腺瘤组(≤10 mm,n = 75)和大腺瘤组(10 - 40 mm,n = 34)。

结果

术后1个月,PRL水平下降了87%(P < 0.001),12个月时下降了93%(P < 0.001)。接受手术和DA治疗12个月后,77.1%的患者实现了生化缓解。在观察的患者总数中,15.6%(n = 17)的Knosp评分大于3。此外,在大腺瘤组中,Knosp评分大于3的患者百分比为41.2%,与微腺瘤组(4%)相比显著更高(P < 0.001)。在微腺瘤患者中,发现患者年龄与肿瘤大小呈弱负相关(r = -0.258,P < 0.026)和正相关(r = 0.251,P < 0.030)。在大腺瘤组中,仅发现术前血清PRL水平与肿瘤大小之间存在显著关联(r = 0.412,P < 0.016)。术前PRL可作为PSPA患者早期生化缓解缺乏的诊断标志物,诊断准确性为66.9%。

结论

本研究发现,对于微泌乳素瘤和大泌乳素瘤患者,经蝶窦原发性手术是控制PRL水平的有效治疗方法。正确且全面地选择手术候选者对于绝大多数患者术后血清PRL正常化至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c68/10875013/d3b2786f9e3f/fsurg-11-1283179-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验